Chloroquine-induced lipidosis mimicking Fabry disease (Q41913027)

14 October 2017

Chloroquine-induced lipidosis mimicking Fabry disease (English)

1 reference

14 October 2017

0 references

1 reference

Diana Albay

1

1 reference

14 October 2017

Sharon G Adler

2

1 reference

14 October 2017

Jaya Philipose

3

1 reference

14 October 2017

C C Calescibetta

4

1 reference

14 October 2017

Stephen G Romansky

5

1 reference

14 October 2017

Arthur H Cohen

6

1 reference

14 October 2017

1 May 2005

1 reference

14 October 2017

1 reference

14 October 2017

18

1 reference

14 October 2017

5

1 reference

14 October 2017

733-738

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.3800344

14 October 2017

0 references

cites work

Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Fabry disease: Diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Amiodarone pulmonary toxicity: functional and ultrastructural evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

The effects of oral chloroquine administration on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Nephrotic syndrome and renal failure associated with a novel glycolipid storage disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Chloroquine-induced cytosomes with curvilinear profiles in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800344

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.3800344

1 reference

Dimensions Publication ID

14 October 2017

0 references

1 reference